The Patient-Centered Outcomes Research Institute approved awards totaling more than $64 million to fund five large patient-centered comparative effectiveness research studies concentrating on cancer, back pain and stroke.
The Oncology Research Information Exchange Network, a precision cancer research collaboration founded by Moffitt Cancer Center and The Ohio State University Comprehensive Cancer Center, announced the addition of four cancer centers Feb. 23, bringing its membership to six.
The recent announcement by the Innovation Center at the Center for Medicare and Medicaid Services regarding the launch of an Oncology Care Model is an important step toward patient-centered cancer care.
A group of eight past chairs of the MD Anderson Cancer Center Faculty Senate have weighed into the controversy over leadership and morale at the Houston-based hospital.
FDA granted accelerated approval to Ibrance (palbociclib) to treat metastatic breast cancer.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
Investigators with The Cancer Genome Atlas Research Network discovered genomic differences in head and neck cancers caused by infection with the human papillomavirus. Researchers also uncovered new smoking-related cancer subtypes and potential new drug targets, and found numerous genomic similarities with other cancer types.
An analysis comparing sentinel lymph node biopsy procedures using Lymphoseek (technetium Tc 99m tilmanocept) injection and vital blue dye to filtered sulfur colloid and VBD in breast cancer patients showed that Lymphoseek patients had significantly fewer sentinel lymph nodes removed per procedure (mean: 1.85 vs. 3.24; p < 0.0001).
Decades after undergoing cranial irradiation for childhood cancer, researchers at St. Jude Children’s Research Hospital found that adult survivors of pediatric cancer remain at risk for pituitary hormone deficiencies that may diminish their health and quality of life. The study included 748 St. Jude survivors of leukemia, brain and other cancers whose treatment included brain... […]
Researchers found that a newer member of the taxane family, cabazitaxel, has properties that could make it more effective for some prostate cancer patients.Researchers also found a genomic marker that could help physicians identify which patients might benefit most from cabazitaxel.
